Frequency, type, and monetary value of financial conflicts of interest in cancer clinical research

Journal of Clinical Oncology

Volumn 25, Issue 24, 2007, Pages 3609-3614

  Hampson, Lindsay A ^a   Joffe, Steven ^a   Fowler, Robert ^a   Verter, Joel ^a   Emanuel, Ezekiel J ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RESEARCH; CLINICAL RESEARCH; EMPLOYEE ATTITUDE; FINANCIAL MANAGEMENT; FUNDING; PRIORITY JOURNAL;

BIOMEDICAL RESEARCH; CONFLICT OF INTEREST; DISCLOSURE; ETHICS, RESEARCH; HUMANS; MEDICAL ONCOLOGY; SCIENTIFIC MISCONDUCT;

EID: 34548501763     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.3633     Document Type: Article

References (28)

1. Bekelman JE, Li Y, Gross CP: Scope and impact of financial conflicts of interest in biomedical research: A systematic review. JAMA 289:454-465, 2003
2. Clifford TJ, Barrowman NJ, Moher D: Funding source, trial outcome and reporting quality: Are they related? Results of a pilot study. BMC Health Serv Res 2:18-23, 2002
3. Djulbegovic B, Lacevic M, Cantor A, et al: The uncertainty principle and industry-sponsored research. Lancet 356:635-638, 2000
4. Neumann PJ, Sandberg EA, Bell CM, et al: Are pharmaceuticals cost-effective? A review of the evidence. Health Aff 19:92-109, 2000
5. Knox KS, Adams JR, Djulbegovic B, et al: Reporting and dissemination of industry versus non-profit sponsored economic analyses of six novel drugs used in oncology. Ann Oncol 11:1591-1595, 2000
6. Kjaergard LL, Nikolova D, Gluud C: Randomized clinical trials in Hepatology: Predictors of quality. Hepatology 30:1134-1138, 1999
7. Cho MK, Bero LA: The quality of drug studies published in symposium proceedings. Ann Intern Med 124:485-489, 1996
8. Massie BM, Rothenberg D: Impact of pharmaceutical industry funding of clinical research: Results of a survey of antianginal trials. Circulation 70:390s, 1984 (suppl 2)
9. Blumenthal D, Gluck M, Louis KS, et al: University-industry research relationships in biotechnology: Implications for the university. Science 232:1361-1366, 19867
10. Rochon PA, Gurwitz JH, Simms RW, et al: A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med 154:157-163, 1994
11. Blumenthal D, Campbell EG, Causino N, et al: Participation of life-science faculty in research relationships with industry. N Engl J Med 335:1734-1739, 1996
12. Rennie D: Thyroid storm. JAMA 277:1238-1243, 1997
13. Melander H, Ahlqvist-Rastad J, et al: Evidence b(i)ased medicine: Selective reporting from studies sponsored by pharmaceutical industry: Review of studies in new drug applications. BMJ 326:1171-1173, 2003
14. Whittington CJ, Kendall T, Fonagy P, et al: Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. Lancet 363:1341-1345, 2004
15. Office of New York State Attorney General (OAG) Eliot Spitzer: Settlement sets new standard for release of drug information. New York, NY, OAG, 2005
16. Krimsky S, Rothenberg LS, Stott P, et al: Financial interests of authors in scientific journals: A pilot study of 14 publications. Sci Eng Ethics 2:395-410, 1996
17. Krimsky S, Rothenberg LS, Stott P, et al: Scientific journals and their authors' financial interests: A pilot study. Psychother Psychosom 67:194-201, 1998
18. Boyd EA, Bero LA: Assessing faculty financial relationships with industry: A case study. JAMA 284:2209-2214, 2000
19. Friedberg M, Saffran B, Stinson TJ, et al: Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 282:1453-1457, 1999
20. Perlis RH, Perlis CS, Wu Y, et al: Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am J Psychiatry 162:1957-1960, 2005
21. Brown SD, Daly JC, Kalish LA, et al: Financial disclosures of scientific papers presented at the 2003 RSNA Annual Meeting: Association with reporting of non-Food and Drug Administration-approved uses of industry products. Radiology 239:849-855, 2006
22. Gross CP, Gupta AR, Krumholz HM: Disclosure of financial competing interests in randomised controlled trials: Cross sectional review. BMJ 326:526-527, 2003
23. Campbell EG, Louis KS, Blumenthal D: Looking a gift horse in the mouth: Corporate gifts supporting life sciences research. JAMA 279:995-999, 1998
24. American College of Cardiology: 56th Annual Scientific Session: Abstract policies and procedures. http://acc07.acc.org/
25. American Thoracic Society: Faculty disclosure slide template. http://www.thoracic.org/sections/meetings-and-courses/intemational-conference/ 2007/speaker-guidelines/pages/faculty-disclosure-slide-template.html
26. American Academy of Family Physicians: Rules and regulations for submission. http://www.aafp.org/online/en/home/cme/aafpcourses/conferences/ assembly/presentpaper/rules.htmr#Parsys0009
27. American Academy of Dermatology: Program/presentation submission information: 66th Annual Meeting. http://www.aad.org/EducationAbstract/
28. American Society of Clinical Oncology: American Society of Clinical Oncology: Revised conflict of interest policy. J Clin Oncol 21:2394-2396, 2003